Details der Publikation - CADTH Canadian Drug Expert Committee recommendation

CADTH Canadian Drug Expert Committee recommendation : indication : chronic hepatitis C virus infectionSofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX; Vosevi) be reimbursed for the treatment of adult patients with chronic hepatitis C virus (HCV) infection, without cirrhosis or with compensated cirrhosis, who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor; or genotype 1, 2, 3, or 4 infection and have been previously treated with an HCV regimen containing SOF without an NS5A inhibitor, if the following conditions are met. The patient is under the care of a physician with experience in the diagnosis and management of HCV infection. Drug plan cost for SOF/VEL/VOX should not exceed the drug plan cost for SOF/VEL..

Medienart:	E-Book

Erscheinungsjahr:	January 2018
Erschienen:	Ottawa (ON): CADTH ; January 2018
Ausgabe:	Version 1.0.

Reihe:	CADTH common drug review

Sprache:	Englisch

Links:	www.ncbi.nlm.nih.gov [teilw. kostenfrei]

Themen:	Antiviral Agents Canada Carbamates Drug Combinations Drug Costs Hepatitis C, Chronic Insurance, Health, Reimbursement Sofosbuvir Sulfonamides

Anmerkungen:	"Final.". - Description based on online resource; title from PDF title page (viewed March 20, 2019)

Umfang:	1 online resource (1 PDF file (7 pages)).

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1773194747

Internformat


LEADER	01000cam a22002652 4500
001	1773194747
003	DE-627
005	20230428012022.0
007	cr uuu---uuuuu
008	211011s2018 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)1773194747
035			\|a (DE-599)KEP068698887
035			\|a (NCBI)1740713
035			\|a (EBP)068698887
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
110	2		\|a CADTH Canadian Drug Expert Committee, \|e verfasserin \|4 aut
245	1	0	\|a CADTH Canadian Drug Expert Committee recommendation \|b indication : chronic hepatitis C virus infectionSofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.)
250			\|a Version 1.0.
264		1	\|a Ottawa (ON) \|b CADTH \|c January 2018
300			\|a 1 online resource (1 PDF file (7 pages)).
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
490	0		\|a CADTH common drug review
500			\|a "Final.". - Description based on online resource; title from PDF title page (viewed March 20, 2019)
520			\|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX; Vosevi) be reimbursed for the treatment of adult patients with chronic hepatitis C virus (HCV) infection, without cirrhosis or with compensated cirrhosis, who have: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor; or genotype 1, 2, 3, or 4 infection and have been previously treated with an HCV regimen containing SOF without an NS5A inhibitor, if the following conditions are met. The patient is under the care of a physician with experience in the diagnosis and management of HCV infection. Drug plan cost for SOF/VEL/VOX should not exceed the drug plan cost for SOF/VEL.
650		2	\|a Hepatitis C, Chronic \|x drug therapy \|0 https://id.nlm.nih.gov/mesh/D019698Q000188
650		2	\|a Antiviral Agents \|x therapeutic use \|0 https://id.nlm.nih.gov/mesh/D000998Q000627
650		2	\|a Antiviral Agents \|x economics \|0 https://id.nlm.nih.gov/mesh/D000998Q000191
650		2	\|a Sofosbuvir \|x therapeutic use \|0 https://id.nlm.nih.gov/mesh/D000069474Q000627
650		2	\|a Sofosbuvir \|x economics \|0 https://id.nlm.nih.gov/mesh/D000069474Q000191
650		2	\|a Sulfonamides \|x therapeutic use \|0 https://id.nlm.nih.gov/mesh/D013449Q000627
650		2	\|a Sulfonamides \|x economics \|0 https://id.nlm.nih.gov/mesh/D013449Q000191
650		2	\|a Carbamates \|x therapeutic use \|0 https://id.nlm.nih.gov/mesh/D002219Q000627
650		2	\|a Carbamates \|x economics \|0 https://id.nlm.nih.gov/mesh/D002219Q000191
650		2	\|a Drug Combinations \|0 https://id.nlm.nih.gov/mesh/D004338
650		2	\|a Drug Costs \|0 https://id.nlm.nih.gov/mesh/D016527
650		2	\|a Insurance, Health, Reimbursement \|0 https://id.nlm.nih.gov/mesh/D007349
651		2	\|a Canada \|0 https://id.nlm.nih.gov/mesh/D002170
710	2		\|a Canadian Agency for Drugs and Technologies in Health, \|e MitwirkendeR \|4 ctb
856	4	0	\|u https://www.ncbi.nlm.nih.gov/books/NBK533004/ \|m X:NCBI \|x Verlag \|z teilw. kostenfrei
912			\|a ZDB-193-NCB
912			\|a GBV_ILN_22
912			\|a ISIL_DE-18
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_22_i06404
912			\|a GBV_ILN_40
912			\|a ISIL_DE-7
912			\|a GBV_ILN_74
912			\|a ISIL_DE-354
912			\|a GBV_ILN_2003
912			\|a ISIL_DE-25
912			\|a GBV_ILN_2009
912			\|a ISIL_DE-180
912			\|a GBV_ILN_2010
912			\|a ISIL_DE-15
951			\|a BO
980			\|2 22 \|1 01 \|x 0018 \|b 399409156X \|h h64 NCBI \|y zi06404 \|z 21-10-21
980			\|2 40 \|1 01 \|x 0007 \|b 399401784X \|h OLR-NCB-BOOKSHELF \|y xsn \|z 21-10-21
980			\|2 74 \|1 01 \|x 0354 \|b 3999794437 \|c 09 \|f E-Bibl \|d EM 0000 \|e --%%-- \|j --%%-- \|y ze \|z 08-11-21
980			\|2 2003 \|1 01 \|x DE-25 \|b 3995684653 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j n \|k Elektronischer Volltext - Open Access \|y l01 \|z 25-10-21
980			\|2 2009 \|1 01 \|x DE-180 \|b 3987684674 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 11-10-21
980			\|2 2010 \|1 01 \|x DE-15 \|b 3987771267 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j n \|k Elektronischer Volltext - Open Access \|y l01 \|z 11-10-21
981			\|2 22 \|1 01 \|x 0018 \|r https://www.ncbi.nlm.nih.gov/books/NBK533004/
981			\|2 40 \|1 01 \|x 0007 \|y Volltext, Open Access \|r https://www.ncbi.nlm.nih.gov/books/NBK533004/
981			\|2 74 \|1 01 \|x 0354 \|r https://www.ncbi.nlm.nih.gov/books/NBK533004/
981			\|2 2003 \|1 01 \|x DE-25 \|r https://www.ncbi.nlm.nih.gov/books/NBK533004/
981			\|2 2010 \|1 01 \|x DE-15 \|y Online-Zugriff \|r https://www.ncbi.nlm.nih.gov/books/NBK533004/
985			\|2 22 \|1 01 \|x 0018 \|a h64 ebook
985			\|2 74 \|1 01 \|x 0354 \|a EM 0000
995			\|2 22 \|1 01 \|x 0018 \|a h64 NCBI
995			\|2 22 \|1 01 \|x 0018 \|a h64 freie Ressource
995			\|2 40 \|1 01 \|x 0007 \|a OLR-NCB-BOOKSHELF

CADTH Canadian Drug Expert Committee recommendation : indication : chronic hepatitis C virus infectionSofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.)

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände